UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

68.50EUR
5 Mar 2015
Change (% chg)

€0.26 (+0.38%)
Prev Close
€68.24
Open
€68.68
Day's High
€69.26
Day's Low
€68.15
Volume
357,676
Avg. Vol
311,645
52-wk High
€75.62
52-wk Low
€54.53

UCB.BR

Chart for UCB.BR

About

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.58
Market Cap(Mil.): €13,335.31
Shares Outstanding(Mil.): 194.51
Dividend: 0.78
Yield (%): 1.14

Financials

  UCB.BR Industry Sector
P/E (TTM): 51.44 38.99 40.21
EPS (TTM): 1.33 -- --
ROI: 2.91 17.01 16.34
ROE: 5.35 17.53 17.27
Search Stocks

UCB sees three newer drugs driving 2015 income increase

BRUSSELS - Belgian pharmaceutical company UCB forecast improved income in 2015 on Friday based on continued growth of its three newer drugs, although its profit outlook is not as bullish as that of the market.

27 Feb 2015

UCB sees three newer drugs driving 2015 income increase

BRUSSELS, Feb 27 - Belgian pharmaceutical company UCB forecast improved income in 2015 on Friday based on continued growth of its three newer drugs, although its profit outlook is not as bullish as that of the market.

27 Feb 2015

BRIEF-UCB full-year net profit rises 37 pct

* FY revenue of 3 344 million euros, +7 pct or +8 pct at constant currencies

27 Feb 2015

BRIEF-UCB advances Neupro in China

* Announced positive top-line results from two phase 3 studies evaluating Neupro in treatment of patients in China

05 Feb 2015

BRIEF-Theradiag enters into master services agreement with UCB

* Entered into a master services agreement with UCB, with a first application for anti-TNF biologic certolizumab pegol (brand name Cimzia)

03 Feb 2015

BRIEF-UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

* UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

21 Jan 2015

BRIEF-UCB, Neuropore to develop Parkison's treatment

* Neuropore Therapies Inc and UCB enter into world-wide collaboration and agreement

16 Jan 2015

BRIEF-UCB, Advent International and Avista Capital Partners terminate acquisition of Kremers Urban

* UCB, Advent International and Avista Capital Partners mutually agree to terminate acquisition agreement for Kremers Urban

16 Dec 2014

BRIEF-UCB announces partnership with Daiichi Sankyo in Japan

* Announces partnership with Daiichi Sankyo for co-commercialization of Lacosamide in Japan

28 Nov 2014

BRIEF-UCB Phase 3 clinical study on VIMPAT meets primary efficacy endpoint

* Phase 3 clinical study evaluating VIMPAT (lacosamide) meets its primary efficacy endpoint

28 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks